On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

WISP3

cellular communication network factor 6

Chromosome 6q21 Autosomal recessive HGNC:12771 Tier C
WISP3 6q21 p arm q arm 6

WISP3 is located on the long (q) arm of chromosome 6, at band 6q21. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 6 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

WISP3 is located on chromosome 6 and encodes cellular communication network factor 6, a member of the CCN family of matricellular proteins. These proteins do not provide structural support themselves but instead modulate interactions between cells and their surrounding matrix, influencing processes such as cell adhesion, migration, and differentiation. WISP3 plays a particularly important role in cartilage homeostasis, where it helps coordinate the balance between matrix synthesis and degradation. The gene follows an autosomal recessive inheritance pattern, meaning that pathogenic variants in both copies are required to cause disease. WISP3-related conditions are included in UK NHS carrier screening pathways for skeletal dysplasias.

What the gene does

The WISP3 protein is secreted into the extracellular space surrounding cells, particularly within cartilage and other connective tissues. Once outside the cell, it interacts with various components of the extracellular matrix and with cell-surface receptors to regulate cellular behaviour. Research suggests that WISP3 helps maintain the structural integrity of cartilage by modulating the activity of enzymes that break down matrix components, thereby preventing excessive tissue degradation. The protein also appears to influence chondrocyte function, supporting the cells responsible for producing and maintaining cartilage throughout life. Evidence indicates that WISP3 participates in growth factor signalling pathways that coordinate skeletal development and joint maintenance. When WISP3 function is lost, the normal balance between cartilage synthesis and breakdown is disrupted, leading to progressive deterioration of joint surfaces and the skeletal abnormalities observed in affected individuals.

Video: Genetics 101

Chromosome location

WISP3 is located on the long arm of chromosome 6 at position 6q21. This chromosomal region contains several genes involved in skeletal development and connective tissue function. The gene spans multiple exons that encode the 354-amino-acid protein, with the coding sequence organised to produce distinct functional domains essential for protein secretion and extracellular activity.

Protein structure

The WISP3 protein comprises 354 amino acids organised into three principal functional domains. The IGFBP N-terminal domain spans amino acids 44 to 117 and shares structural similarity with insulin-like growth factor binding proteins, suggesting a role in growth factor interaction. The TSP type-1 domain, located at amino acids 208 to 253, is characteristic of thrombospondin family proteins and typically mediates protein-protein interactions within the extracellular matrix. The C-terminal CTCK domain occupies amino acids 268 to 342 and contains a conserved cysteine-knot motif common to many secreted signalling proteins, providing structural stability and facilitating receptor binding. This modular architecture enables WISP3 to interact with multiple partners in the extracellular environment.

Domain map · 354 amino acids
IGFBP N-terminal (44-117)TSP type-1 (208-253)CTCK (268-342)IGFBP N-terminal44-117TSP type-1208-253CTCK268-3421~177354
Domain - independent functional unit
🧬 Explore 3D structure on AlphaFold
UniProt:O95389Length:354 aaStructure:AlphaFold

Key variants

Pathogenic variants in WISP3 typically result in loss of protein function, either through premature termination of translation, disruption of critical domain structure, or impaired protein secretion. Because the condition follows autosomal recessive inheritance, individuals require pathogenic variants in both gene copies to develop skeletal abnormalities. Carriers with one pathogenic variant generally remain asymptomatic. The majority of disease-causing variants are nonsense or frameshift changes that prevent production of functional protein, though missense variants affecting key structural domains have also been reported.

No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.

Associated conditions

Biallelic pathogenic variants in WISP3 cause progressive pseudorheumatoid dysplasia, an autosomal recessive skeletal disorder that typically manifests in childhood. Affected individuals experience progressive joint stiffness, swelling, and pain, particularly in the hands, knees, and hips, often mistaken for juvenile arthritis in initial presentations. Unlike true rheumatoid conditions, however, inflammatory markers remain normal and the condition stems from cartilage degeneration rather than immune-mediated inflammation. Progressive loss of joint mobility and skeletal deformity develop over time, with considerable variation in severity between individuals.

  • Progressive pseudorheumatoid dysplasia
    Skeletal
    AR
    Dedicated page coming soon

Inheritance pattern

Conditions caused by pathogenic WISP3 variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous WISP3 carrier status across ancestry groups?

UK clinical status

WISP3 is included on the NHS Genomic Medicine Service Skeletal dysplasia panel with green classification (R104 evidence level), indicating strong evidence supporting its clinical validity for diagnostic testing. This classification reflects the gene's established role in skeletal disorders and guides its use in NHS genomic testing pathways for individuals presenting with progressive joint and skeletal abnormalities.

Green-listed
High evidence · clinically actionable in NHS testing
Included in NHS GMS signed-off panels

Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory

Frequently asked questions

How is WISP3-related skeletal dysplasia inherited?

Progressive pseudorheumatoid dysplasia follows autosomal recessive inheritance, meaning an individual must inherit pathogenic variants in both copies of WISP3 to develop the condition. Parents who each carry one variant typically show no symptoms but have a 25% chance with each pregnancy of having an affected child.

What distinguishes WISP3-related joint disease from rheumatoid arthritis?

Though WISP3-related progressive pseudorheumatoid dysplasia presents with joint swelling and stiffness resembling arthritis, it results from cartilage degeneration rather than immune system dysfunction. Affected individuals lack the inflammatory markers and antibodies characteristic of true rheumatoid conditions, and the disease does not respond to immunosuppressive therapies.

At what age does WISP3-related skeletal dysplasia typically appear?

Symptoms generally emerge in early to mid-childhood, often between ages 3 and 8, with progressive joint stiffness and swelling developing over subsequent years. The rate of progression and severity varies considerably between affected individuals.

Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 17 April 2026. Content compiled from HGNC · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .